30 Oct 2025 | 5 Mins Read
Deven Choksey recommends buying Dr Reddy's Laboratories
Flipitmoney
Deven Choksey's report states Dr Reddy's Laboratories Q2FY26 revenue rose 9.8% YoY to INR 88,283 Mn, driven by growth in Europe (+139%), India (+13%), and Emerging Markets (+14%). However, North America declined 13% YoY due to price erosion and lower Lenalidomide sales. Dr Reddy's Lab valuation is set at 19.0x Sep'27 EPS, implying a target price of INR 1,140.